Table 3 Access to help for concerns regarding physical changes after cancer treatment P-values are from the Cochran-Armitage test for trend across income categories

Fatigue/

tiredness

297

(43%)

N = 697

448

(36%)

N = 1,258

198

(29%)

N = 674

185

(29%)

N = 631

< 0001

104

(36%)

N = 291

159

(36%)

N = 443

72

(36%)

N = 198

61

(33%)

N = 183

0.67

Changes in sexual activities/

function

122

(39%)

N = 316

302

(38%)

N = 795

199

(38%)

N = 521

239

(45%)

N = 535

0.04

47

(39%)

N = 120

120

(40%)

N = 299

68

(34%)

N = 198

85

(36%)

N = 238

0.26

Changes in concentration or memory

115

(31%)

N = 370

154

(25%)

N = 615

62

(20%)

N = 303

50

(18%)

N = 282

< 0.001

63

(56%)

N = 113

70

(47%)

N = 149

29

(48%)

N = 61

25

(51%)

N = 49

0.46

Nerve problems

187

(53%)

N = 351

329

(53%)

N = 624

158

(47%)

N = 334

131

(47%)

N = 276

0.05

75

(41%)

N = 184

128

(39%)

N = 326

72

(46%)

N = 156

53

(41%)

N = 130

0.59

Gastro-intestinal problems

284

(66%)

N = 429

471

(63%)

N = 742

226

(60%)

N = 377

216

(60%)

N = 362

0.03

87

(31%)

N = 280

113

(24%)

N = 465

64

(28%)

N = 225

67

(31%)

N = 213

0.65

Bladder or urinary problems

249

(63%)

N = 396

470

(58%)

N = 817

267

(60%)

N = 444

272

(58%)

N = 473

0.28

65

(26%)

N = 248

85

(18%)

N = 463

61

(23%)

N = 265

63

(23%)

N = 272

0.94

Chronic pain or long-term pain

258

(64%)

N = 401

326

(58%)

N = 567

149

(56%)

N = 268

112

(50%)

N = 224

< 0.001

87

(34%)

N = 254

108

(33%)

N = 323

56

(38%)

N = 148

41

(37%)

N = 112

0.47

Hormonal, menopause or fertility

81

(47%)

N = 171

148

(42%)

N = 351

86

(42%)

N = 205

78

(46%)

N = 171

0.81

37

(47%)

N = 79

50

(34%)

N = 145

29

(35%)

N = 84

27

(35%)

N = 77

0.18

Lymphedema

176

(64%)

N = 277

229

(57%)

N = 404

112

(62%)

N = 180

87

(61%)

N = 142

0.87

43

(25%)

N = 174

56

(25%)

N = 228

30

(27%)

N = 112

23

(26%)

N = 87

0.66